Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease
July 19, 2022 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to...
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
July 12, 2022 16:05 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split
July 05, 2022 07:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
May 04, 2022 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Provides Clinical and Corporate Update
January 04, 2022 05:00 ET
|
Allena Pharmaceuticals, Inc.
ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety...
Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference
November 15, 2021 16:05 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop...
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress
November 10, 2021 16:05 ET
|
Allena Pharmaceuticals, Inc.
ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track...
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease
November 03, 2021 08:00 ET
|
Allena Pharmaceuticals, Inc.
- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract - - Patients with gout and CKD have a serious condition with an unmet need for urate-lowering–therapies – ...
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346
September 29, 2021 08:00 ET
|
Allena Pharmaceuticals, Inc.
- Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease - - Novel therapeutic candidate targets uric acid in the GI tract - - Initial data...
Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference
September 09, 2021 08:30 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop...